Rosetta Genomics Reports Rise in Q1 Revenues and Loss; Suspends Guidance | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics today reported a slight rise in its first-quarter revenues and a 6 percent increase in its net loss year over year.

The microRNA-based diagnostics firm reported total revenues of $27,000 for the three-month period ended March 31, compared to $17,000 for the first quarter of 2009.

Rosetta's net loss for the quarter was $3.6 million, or $.22 per share, compared to $3.4 million, or $.30 per share, for Q1 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.